C4 Therapeutics (CCCC) vs Opus Genetics (IRD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Opus Genetics (IRD) has outperformed C4 Therapeutics (CCCC) over the past year, gaining 117.2% versus a gain of 24.8%. Over five years, IRD leads with a +2.8% price change compared with -93.6% for CCCC. Opus Genetics is the larger company by market cap ($366.9 million vs $346.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CCCC | IRD |
|---|---|---|
| Share price | $2.82 | $4.41 |
| Market cap | $346.93M | $366.89M |
| 1-day change | -2.08% | +0.68% |
| YTD return | +47.64% | +119.40% |
| 1-year return | +24.78% | +117.24% |
| 5-year return | -93.57% | +2.80% |
| EPS (TTM) | $-0.91 | $-1.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.17 | $7.07 |
| 52-week low | $1.69 | $1.70 |
| Distance from 52-week high | -45.45% | -37.62% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +372.70% | +204.08% |
| Average volume | 2.38M | 2.37M |
| Shares outstanding | 123.03M | 83.20M |
| Employees | 104 | 27 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IRD has outperformed CCCC by 92.5 percentage points over the past year.
About C4 Therapeutics
CCCC stock →C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 104 employees
About Opus Genetics
IRD stock →Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees
CCCC vs IRD FAQ
Which is bigger, C4 Therapeutics or Opus Genetics?
Opus Genetics (IRD) is larger, with a market capitalization of $366.89M compared with $346.93M for C4 Therapeutics (CCCC).
Which stock has performed better over the past year, CCCC or IRD?
IRD returned +117.24% over the past 12 months, compared with +24.78% for CCCC (price return, excluding dividends). Past performance does not predict future results.
Are C4 Therapeutics and Opus Genetics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for C4 Therapeutics and Biotechnology: Pharmaceutical Preparations for Opus Genetics.